Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Tenalisib |
| Trade Name | |
| Synonyms | RP6530|RP-6530|RP 6530 |
| Drug Descriptions |
Tenalisib (RP6530) is an inhibitor of PIK3CG and PIK3CD, which blocks PI3K/AKT signaling to prevent cell proliferation and also may modulate the tumor microenvironment and induce macrophage phenotype conversion from M2 to M1 (PMID: 30352904, PMID: 31761713, PMID: 32824175). |
| DrugClasses | PIK3CD inhibitor 27 PIK3CG inhibitor 10 |
| CAS Registry Number | 1639417-53-0 |
| NCIT ID | C113433 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cyclophosphamide + Doxorubicin + Prednisone + Tenalisib + Vincristine Sulfate | Cyclophosphamide Doxorubicin Prednisone Tenalisib Vincristine Sulfate | 0 | 1 |
| Pembrolizumab + Tenalisib | Pembrolizumab Tenalisib | 0 | 1 |
| Romidepsin + Tenalisib | Romidepsin Tenalisib | 0 | 1 |
| Ruxolitinib + Tenalisib | Ruxolitinib Tenalisib | 1 | 0 |
| Tenalisib | Tenalisib | 0 | 3 |